All these experiments showed that treatment of CD6-ADC substantially eliminated the pathogenic human T cells and attenuated GVHD in mice, suggesting that the CD6-ADC can be used to treat T cell–mediated disorders such as GVHD in additional to autoimmune uveitis. Here, CD6 is linked to autoimmune uveitis.